HercepTest
Agilent Technologies Singapore (International) Pte , Ltd. · Decision date Jan 28, 2026
What did the FDA approve?
FDA records P980018/S026 as a supplement to PMA P980018, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jan 28, 2026.
FDA approval order statement
Approval for specific labeling change to provide clearer instructions for use, which will improve user compliance and reduce errors, thereby ensuring consistent staining results.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Pathology
- Decision date
- Jan 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P980018/S026
- Regulatory pathway
- PMA supplement
- Product code
- MVC
- Decision code
- APPR
- Decision date
- Jan 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.
- Product code
- MVC
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980018. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980018 · Original PMA
DAKO HERCEPTEST
P980018/S026 received
Application receipt date recorded by FDA.
P980018/S026 · FDA decision
Special (Immediate Track)
P980018/S027 · Related supplement
HercepTest
Timeline entries are records held by MedtechLedger for P980018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DAKO HERCEPTESTP980018 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA approval | Sep 25, 1998 | FDA |
HercepTestP980018/S027 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
Explore the linked device profile
Other records with product code MVC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ventana Medical Systems, Inc. | PMA supplement | Aug 25, 2026 | FDA | |
BOND Oracle HER2 IHC SystemP090015/S014 | Leica Biosystems | PMA supplement | Jun 4, 2026 | FDA |
| Ventana Medical Systems, Inc. | PMA supplement | May 15, 2026 | FDA | |
| Ventana Medical Systems, Inc. | PMA supplement | Dec 15, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies Singapore (International) Pte , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- # 1 Yishun Ave. 7, Singapore, 768923
Sources and methodology
- Original FDA record: P980018/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



